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SUMMARY 
 
The occurrence of cognitive disturbances upon CNS inflammation or infection has been 
correlated to increased levels of the cytokine tumour necrosis factor-α (TNFα). To-date, 
however, no specific mechanism via which this cytokine could alter cognitive circuits has 
been demonstrated. Here we show that local increase of TNFα in the hippocampal dentate 
gyrus activates astrocyte TNF receptor type 1 (TNFR1), which in turn triggers an astrocyte-
neuron signaling cascade that results in persistent functional modification of hippocampal 
excitatory synapses. Astrocytic TNFR1 signaling is necessary for the hippocampal synaptic 
alteration and contextual learning-memory impairment observed in experimental autoimmune 
encephalitis (EAE), an animal model of Multiple Sclerosis (MS). This process may contribute 
to the pathogenesis of cognitive disturbances in MS as well as other CNS conditions 
accompanied by inflammatory states or infections. 
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INTRODUCTION 
 
Synaptic activity is subject to various types of control, including regulatory inputs from 
surrounding glial cells. The release of gliotransmitters and factors from astrocytes induces 
synaptic modulation in cognitive circuits (reviewed in Araque et al. (2014)) and could 
contribute to cognitive function (Halassa et al., 2009; Han et al., 2012; Lee et al., 2014; 
Suzuki et al., 2011). An astrocyte-synapse modulatory pathway was described in the 
hippocampal dentate gyrus (DG) by which synaptically-activated astrocyte G protein-coupled 
receptors (GPCR) stimulate, via glutamate release, NR2B-containing NMDA receptors 
located in presynaptic excitatory fibers (pre-NMDAR, Jourdain et al. (2007)), resulting in 
transient strengthening of entorhinal cortex (EC)-hippocampal DG excitatory synapses 
(Jourdain et al., 2007), a circuit implicated in contextual learning and memory (Denny et al., 
2014; Liu et al., 2012). Surprisingly, the glial regulatory pathway is itself controlled by the 
cytokine TNFα (Santello et al., 2011). Moreover, TNFα exerts additional controls at 
hippocampal synapses, such as on trafficking of AMPA (Beattie et al., 2002) and GABAA 
receptors (Pribiag and Stellwagen, 2013), emerging as a key physiological regulator of 
hippocampal synaptic function. Therefore, it is important to ask what happens to the 
hippocampal cognitive circuit when TNFα increases above local homeostatic levels (Santello 
and Volterra, 2012), as occurs in the CNS in a variety of medical conditions linked to 
inflammation or infection (Clark et al., 2010).  
Observations in both humans and animals indicate a link between increased TNFα levels and 
cognitive alterations (Swardfager and Black, 2013; Yirmiya and Goshen, 2011), but data are 
descriptive and no study to date has identified the specific mechanisms. Here, starting from 
the identified characteristics of astrocytic modulation of DG synapses (Jourdain et al., 2007; 
Santello et al., 2011), and the specific observation that TNFα levels above a certain threshold 
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(>300 pM) trigger glutamate release from astrocytes (Bezzi et al., 2001; Domercq et al., 2006; 
Santello et al., 2011), we asked whether such a condition can affect excitatory transmission at 
perforant path-granule cell (PP-GC) hippocampal synapses. We find that high (600 pM) but 
not low (60 pM) TNFα concentrations persistently alter the functional properties of this 
synaptic circuit, acting via TNFR1 and a presynaptic mechanism involving NR2B-containing 
NMDAR. We also show that the same synaptic alteration, together with impaired contextual 
memory processing, is present in a murine model of multiple sclerosis (MS), a pathology 
often presenting with cognitive disturbances (Chiaravalloti and DeLuca, 2008). Finally, taking 
advantage of a transgenic mouse model, we directly demonstrate that both synaptic and 
cognitive impairments in the murine MS model depend to a large extent on activation of 
TNFR1 in astrocytes. 
 
 
 
RESULTS 
 
Increased TNFα persistently changes excitatory transmission in a hippocampal 
cognitive circuit. 
To establish whether an increased local level of TNFα affects cognitive circuits, we initially 
compared the effects produced on excitatory EC-DG synapses by rapid (10 s) puffs of 
exogenous TNFα, applied at the estimated basal concentration (60 pM, Santello et al. (2011)) 
or at a 10-fold higher concentration (600 pM, Fig. 1). We used this experimental approach to 
evaluate the confined effects of the cytokine in the outer/middle dentate molecular layer 
(OML/MML, Fig. 1A), and to directly link the observed effect to the used concentration. 
Application of 60 pM TNFα did not produce any detectable change in basal synaptic activity 
(mean frequency, amplitude, and kinetics of AMPAR-dependent miniature post-synaptic 
excitatory currents (mEPSCs)) in dentate GCs within 30 min (Fig. 1A-C and Fig. S1). In 
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contrast, application of 600 pM TNFα produced progressive, strong increase in synaptic 
activity that reached plateau within 10 min and persisted unchanged after 30 min (and, in a 
few longer experiments, also after 50-60 min, data not shown). This long-lasting effect of the 
cytokine affected mEPSC frequency selectively, without changing mEPSC amplitude or 
kinetics (Fig. 1A-C and Fig. S1A), suggesting a presynaptic mechanism. When applied via 
prolonged bath incubation (1-2.5 h), 600 pM TNFα, however, in addition to mEPSC 
frequency, also increased mEPSC amplitude, albeit slightly (Fig. S1B), suggesting that its 
action at excitatory synapses is both dose- and time-dependent. These recordings were 
performed in young mice (P17-25), but comparable effects were observed in adult animals 
(P60-90, Fig. 1D) ruling out that the TNFα effect is a developmental phenomenon. Increased 
mEPSC frequency in GCs predicts an enhanced EC drive to the DG. To verify this, we 
recorded EPSCs evoked by lateral PP stimulation (eEPSC) in individual GCs (Fig. 1E-F). 
Brief puffs of 600 pM TNFα, but not 60 pM, induced long-lasting increase in eEPSC 
amplitude and parallel change in short-term plasticity, denoted by reduced paired-pulse 
facilitation upon two consecutive stimuli. We conclude that high TNFα persistently enhances 
glutamate release probability at presynaptic PP terminals, thereby producing aberrant 
excitability of hippocampal GCs. 
 
The TNFα effect requires activation of TNFR1 and ifenprodil-sensitive NMDAR 
Given that TNFα above 300 pM triggers glutamate release from astrocytes and that astrocytic 
glutamate transiently strengthens GC synapses via activation of NR2B-containing pre-
NMDAR (Bezzi et al., 2001; Jourdain et al., 2007; Santello et al., 2011), we tested whether 
the long-lasting synaptic effect of elevated TNFα was sensitive to the NR2B antagonist, 
ifenprodil. Indeed, in the presence of this drug, 600 pM TNFα failed to change mEPSC 
frequency (Fig. 2A). To then check whether TNFα activates NR2B-NMDAR persistently, we 
 6 
applied ifenprodil at the peak of the synaptic effect of the cytokine. The NMDAR antagonist 
was now ineffective at reversing the TNFα increase in mEPSC frequency (Fig. 2B). 
Therefore, the long-lasting synaptic action of TNFα necessitates NR2B-NMDAR activation, 
but only during its induction. We next hypothesized a role for TNFR1, given that specific 
TNFR1 agonist antibodies mimic the glutamate-releasing action of TNFα in astrocytes (Bezzi 
et al., 2001). When we applied 600 pM TNFα to hippocampal slices from tnfr1-/- mice (Rothe 
et al., 1993), the cytokine failed to produce any increase in mEPSC frequency (Fig. 2C), 
although basal activity at GC synapses was normal (mEPSC frequency: wild-type: 1.63 ± 0.23 
Hz (n = 11); tnfr1-/- : 1.87 ± 0.28 (n = 4), p = 0.57; amplitude: wild-type: 7.91 ± 0.74 pA; 
tnfr1-/- : 6.57 ± 0.57, p = 0.32, unpaired t-test). Taken together, these data confirm that TNFR1 
plays a necessary role in the synaptic effect of TNFα and suggest that, at increased levels, the 
cytokine stimulates astrocyte signalling via this receptor.  
 
tnfr1 knockout mice that conditionally re-express the receptor in astrocytes selectively 
To establish that elevated TNFα indeed affects synaptic function via astrocyte signalling, we 
generated a new double transgenic mouse model, the hGFAPcreT2/tnfr1cneo/cneo mouse. To 
obtain this model we crossed mice with TNFR1 conditionally deleted in all cell types 
(tnfr1cneo/cneo, Victoratos et al. (2006)), which behave as functional tnfr1 knockout mice and 
lack any response to 600 pM TNFα at GC synapses (data not shown), with mice allowing 
TNFR1 re-expression selectively in astrocytes via tamoxifen (TAM)-inducible cre 
recombination driven by the human glial fibrillary acidic protein promoter (hGFAPcreT2, 
Hirrlinger et al. (2006), details in Fig. 3A). The efficiency and specificity of astrocytic 
recombination in the hippocampal DG was determined using hGFAPcreT2/tnfr1cneo/cneo mice 
expressing the ROSA-EYFP reporter (Srinivas et al., 2001) (Fig. 3B). Young (P22) and adult 
(P90) mice, studied 13 and 25 days after the first TAM injection, respectively, yielded similar 
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results. In 12 slices from 4 P90 mice we counted a total of 1680 EYFP+ cells, most of which 
displayed the typical morphology of protoplasmic astrocytes and were distributed patchily, 
both in the dentate ML and in the hilus. These cells were also positive for the astrocytic 
marker glutamine synthetase (GS+/EYFP+ cells), and represented 37% of the total astrocytic 
population (GS+ cells). About 10% of the EYFP+ cells were confined to the subgranular zone 
(SGZ), most likely representing stem cells and neuronal precursors. In the MML/OML where 
PP-GC synapses lie, 99.3% (714 cells) of the EYFP+ cells were GS+, representing resident 
astrocytes, while 0.7% (5 cells) were NeuN+ or GS-, representing immature GCs sending 
growing dendrites. No reporter expression was detected in mice injected with corn oil (OIL), 
the TAM vehicle (Fig. S2), confirming that cre activity is specifically induced by TAM. The 
above results were corroborated by genomic PCR analysis of TAM-induced tnfr1 
recombination in FACS-sorted populations of NeuN+ cells (no recombination) and NeuN- 
cells (prominent recombination) obtained from hGFAPcreT2/tnfr1cneo/cneo mouse brains (Fig. 
3C and Fig. S3). Therefore, hGFAPcreT2/tnfr1cneo/cneo mice are a valid model to investigate 
the contribution of astrocyte signalling to the actions of TNFα. 
 
Astrocyte-selective TNFR1 expression largely reconstitutes the synaptic effect of TNFα 
We next investigated whether TNFα has an effect at PP-GC synapses in TAM-injected 
hGFAPcreT2/tnfr1cneo/cneo mice with TNFR1 expression functionally reconstituted selectively 
in astrocytes. Experiments were conducted 10-11 days after TAM onset. Puff of 600 pM 
TNFα locally in the MML/OML significantly increased mEPSC frequency in GCs (Fig. 4A). 
The cytokine effect was slow and persistent, as observed in wild-type mice (Fig. 1B), but less 
pronounced, possibly because only part of the astrocytic population re-expresses TNFR1 (Fig. 
3B). In contrast, application of TNFα to slices from OIL-injected hGFAPcreT2/tnfr1cneo/cneo 
mice (global tnfr1 knockouts, no TAM-induced recombination) produced no synaptic effect 
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(Fig. 4B). Any unspecific effect of TAM was also excluded, since in slices from TAM-
injected tnfr1cneo/cneo mice, in which TAM cannot induce recombination, TNFα did not affect 
mEPSC activity (Fig. 4C). Therefore, expression of TNFR1 exclusively in GFAP-positive 
cells faithfully reproduces the persistent effect of TNFα on mEPSC frequency observed in 
wild-type mice.  
 
Cognitive impairment accompanied by local inflammation and enhanced TNFα levels in 
the hippocampus in a mouse model of multiple sclerosis 
Next we evaluated whether the identified astrocytic cascade triggered by high TNFα and 
causing persistent alteration of a cognitive synaptic circuit, is activated in a defined 
pathological condition and contributes to cognitive pathogenesis. We focused on multiple 
sclerosis (MS) because: (a) about 50% of MS patients suffer from cognitive disturbances 
(Chiaravalloti and DeLuca, 2008) and present anatomical/functional alterations in cognitive 
areas, including hippocampal DG (Gold et al., 2010); (b) in both MS patients and animal 
models of the pathology, notably experimental autoimmune encephalomyelitis (EAE), 
TNFα/TNFR1 signalling is implicated in pathogenesis (Eugster et al., 1999; Gregory et al., 
2012; Kassiotis and Kollias, 2001). Our studies were performed in the EAE mouse model, 
using an adoptive transfer induction protocol (AT-EAE, Codarri et al. (2011); see 
Experimental Procedures), which allows the EAE CNS pathology to develop effectively also 
in TNFR1-deficient mice. We selected a cognitive test assessing functioning of the EC-DG 
circuitry, contextual fear conditioning (Anagnostaras et al., 2001; Denny et al., 2014; Liu et 
al., 2012) and investigated in adult C57BL/6J mice (P60-90) the effects of AT-EAE in its 
early phase (days 6 and 7 after transfer of autoimmune T cells (6-7 dpi), when classical EAE 
symptoms leading to ascending flaccid paralysis are absent (Fig. S5). An initial activity test 
(AT) excluded any confounding motor or emotional deficits due to AT-EAE (Fig. 5A). 
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Moreover, lack of effect on locomotor activity, freezing or rearing, indicated that motor 
function, exploration and normal anxiety state, respectively, were intact (Fig. S6). 
Subsequently, the mice underwent fear conditioning. Both control (sham-treated) and AT-
EAE mice learned proficiently and acquired conditioned fear across the session, with AT-
EAE mice showing a trend to lower freezing (Fig. 5A). The distance moved during 
electroshock was used as a measure of pain sensitivity and there was no effect of AT-EAE 
(Fig. S6). The next day we measured expression of long-term contextual memory. Only 
control mice exhibited the expected level of fear expression that they acquired on day 6. AT-
EAE mice, in contrast, displayed a marked deficit in contextual memory (Fig. 5A). To 
investigate if this deficit was associated with the presence of a local pathology, we next 
performed immunohistochemistry experiments using leukocyte and microglia markers in 
hippocampal tissue (Fig. 5B). Compared to controls, AT-EAE mice (8-14 dpi) showed an 
accumulation of infiltrating leukocytes at the border between 3rd ventricle and DG and CA3 
parenchyma. Moreover, within the parenchyma, microglia displayed the reactive phenotype, 
with enlarged cell bodies and shortened processes. The amount of reactive and/or infiltrating 
cells decreased progressively from the regions contacting the 3rd ventricle to the more distal 
ones, like CA1 and CA2. For simplicity, we refer to this pathology as “local inflammation”. 
We also measured TNFα protein levels in punches of hippocampal tissue obtained (8 dpi) 
from the same mice studied in the contextual memory test (Fig. 5C). The local level of TNFα 
was increased 8-fold in AT-EAE mice compared to controls. The increase was specific to 
dorsal hippocampus, the region bordering the 3rd ventricle, which is integral to the contextual 
learning and memory circuitry (Anagnostaras et al., 2001). Therefore, at a stage of EAE that 
is fully asymptomatic in terms of motor pathology (8 dpi), mice present with overt local 
inflammatory pathology and enhanced TNFα levels in the hippocampus that could account for 
the observed contextual memory defect.  
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Altered hippocampal excitatory transmission in AT-EAE: protective effect of ifenprodil.  
 We next checked the state of the synaptic circuitry supporting contextual memory in AT-
EAE mice (P60-90, 8-14 dpi). The paired-pulse ratio of eEPSCs at PP-GC synapses was 
significantly reduced compared to controls, indicative of an increased glutamate release from 
PP terminals. Consistently, the synaptic input-output relationship was altered, with 
significantly greater eEPSC amplitudes evoked by the same stimulation intensity (Fig. 6A). 
These defects strongly resemble those induced by high TNFα in younger mice (Fig. 1E-F). In 
keeping, AT-EAE mice also displayed significantly higher mEPSC activity in GCs than 
controls (Fig. 6B). The augmentation was most prominent in mEPSC frequency (34%), less 
pronounced in amplitude (16%), whereas kinetics were unchanged (rise-time: p = 0.19; 
decay-time: p = 0.47, (n = 16) unpaired t-test). Given that ifenprodil prevents the increase in 
mEPSC frequency induced by TNFα in young mice (Fig. 2A), we tested whether the drug 
was effective also in adult AT-EAE mice. In mice treated with ifenprodil in vivo during AT-
EAE induction (see details in Supplementary Experimental Procedures), mEPSC frequency in 
GCs was lower than in untreated AT-EAE mice, and comparable to that in controls (Fig. 6C). 
However, when ifenprodil was applied acutely to slices from untreated AT-EAE mice, the 
drug failed to decrease mEPSC frequency (before ifenprodil: 2.51 ± 0.16 Hz; after ifenprodil: 
2.16 ± 0.18 Hz; n = 8; p = 0.09, paired t-test). These data suggest that NR2B-containing 
NMDAR participate in the induction (but not maintenance) of the persistent change of PP-GC 
excitatory transmission induced by AT-EAE. Intriguingly, the in vivo treatment with 
ifenprodil did not counteract the mEPSC amplitude increase observed in AT-EAE mice (Fig. 
6C), suggesting that this component of the synaptic change is NR2B-independent. 
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Causal role of astrocyte TNFR1 signaling in the hippocampal synaptic alterations and 
cognitive impairment induced by AT-EAE.  
To determine whether the synaptic changes observed in AT-EAE mice depend on TNFα 
acting via astrocyte TNFR1 signalling, we next induced AT-EAE in TAM- or OIL-treated 
adult hGFAPcreT2/tnfr1cneo/cneo mice (See Experimental Procedures for temporal details). 
mEPSC frequency in GCs of TAM-treated AT-EAE mice (astrocyte TNFR1 re-expression) 
was significantly higher than in their OIL-treated counterparts (Fig. 7A) and similar to that 
seen in wild-type AT-EAE mice (Fig. 7B, p = 0.1, unpaired t-test). mEPSC amplitude did not 
differ, however, from that of wild-type AT-EAE mice (p = 0.14, ANOVA followed by post-
hoc comparisons). The effect on mEPSC frequency was not due to TAM per se, because 
TAM-treated AT-EAE tnfr1cneo/cneo mice (no recombination) did not show any increased 
mEPSC frequency (Fig. 7B). All four transgenic groups developed a similar pattern of local 
inflammation in the hippocampal DG, apparently indistinguishable from that seen in wild-
type AT-EAE mice (compare Figs. 7C and 5B), indicating that the TNFR1-dependent 
synaptic changes are triggered downstream of the local inflammatory reaction. To investigate 
whether astrocyte TNFR1 signalling is also responsible for impaired contextual memory in 
AT-EAE mice, we studied three groups of AT-EAE mice: TAM- or OIL-treated 
hGFAPcreT2/tnfr1cneo/cneo and TAM-treated tnfr1cneo/cneo. At 5 dpi, mice were given an open 
field test which excluded any group difference in behaviours relevant to motor function, 
anxiety and exploration (Fig. S7). At 6 dpi, contextual fear conditioning was conducted. All 
three groups demonstrated acquisition of freezing (Fig. 7D), with OIL-treated 
hGFAPcreT2/tnfr1cneo/cneo mice and TAM-treated tnfr1cneo/cneo mice exhibiting a similar 
amount of conditioning, consistent with the absence of any TAM effect. TAM-treated 
hGFAPcreT2/tnfr1cneo/cneo mice exhibited proportionally less acquisition of freezing relative to 
the other two groups. This deficit was not due to reduced sensitivity to the electroshock 
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because all groups moved the same distance during electroshock (Fig. S7). At 7 dpi, mice 
were tested for fear expression. TAM-treated hGFAPcreT2/tnfr1cneo/cneo mice showed a trend 
to decreased freezing relative to the other two groups (Fig. 7D, middle), which was 
proportional to the decreased fear acquisition of the previous day. At 8 dpi, in a second fear 
expression test, TAM-treated hGFAPcreT2/tnfr1cneo/cneo mice exhibited further reduction of 
fear expression and significantly less expression than the two other groups (Fig. 7D, right). 
These data indicate a cognitive phenotype in TAM-treated hGFAPcreT2/tnfr1cneo/cneo mice 
similar to that observed in wild-type AT-EAE mice although the latter presented lower initial 
learning deficit and faster-onset memory deficit, differences that could be due to intrinsic 
variability of the AT-EAE protocol across experiments. We exclude other confounding 
factors because a second open field test conducted at 9 dpi confirmed lack of locomotor and 
exploratory behavioural differences between groups (data not shown). We conclude that 
astrocyte TNFR1 expression is required for both functional alteration of the EC-DG synaptic 
circuit and contextual learning and memory deficit in AT-EAE mice.  
 
 
DISCUSSION 
 
Our study links a local increase in TNFα in the hippocampus to synaptic and cognitive 
dysfunction via astrocyte signalling. This astrocytic pathway is activated in EAE, an animal 
model of multiple sclerosis, and is necessary for the development of the contextual memory 
deficit observed and thus its delineation may reveal new therapeutic targets against cognitive 
decline (discussed below).  
 
Astrocyte TNFR1 is required for induction of synaptic and cognitive defects. 
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In EAE, activated microglia and infiltrating macrophages controlled by CD4+ T cells are the 
most likely cause of local TNFα increase in the DG (Fig. 5B; Renno et al. (1995)), whereas 
downstream activation of TNFR1 in astrocytes appears to be the critical event for induction of 
the core synaptic and behavioural phenotype. This is demonstrated by reconstitution of the 
phenotype in hGFAPcreT2/tnfr1cneo/cneo mice, functional tnfr1 knockouts in which TNFR1, 
via TAM-induced cre recombination, is re-expressed exclusively in GFAP-positive cells. 
Astrocytes represent the only population of such cells that we observed at the time of our 
experiments (10-22 days from the start of recombination) in the dentate OML/MML where 
excitatory PP-GC synapses are located. Recombination in the DG occurs also in the much 
smaller population of SGZ neural stem cells, but expression of TNFR1 in these cells and in 
the derived neuronal precursors and immature GCs very unlikely contributes to the TNFα-
dependent phenotype because: (a) different from astrocytes, these cells lie distally from PP-
GC synapses (25 days after the start of recombination those with growing dendrites able to 
reach the OML/MML were 0.7% of the resident astrocytic population undergoing 
recombination); (b) full integration of newborn GCs into the excitatory network as mature 
GCs requires 8 weeks (Toni et al., 2007), and in any case these cells may contribute to 
contextual memory formation only after 4 weeks of maturation (Gu et al., 2012), a time-frame 
incompatible with the timing of our experiments. 
 
Pathological TNFα contributes to the synaptic alterations: signaling mechanism 
TNFα produces persistent change in excitatory transmission only when its concentration 
increases up to levels that are specific to pathological states. In the early phases of AT-EAE, 
we measured an 8-fold increase in tissue TNFα levels in the dorsal hippocampus. This 
increase resembles in proportion the 10-fold increase that we used to mimic pathological (600 
pM) versus physiological (60 pM) TNFα levels when applying the exogenous cytokine locally 
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in the DG. In absolute value, 600 pM could represent a concentration close to the one reached 
by the cytokine during EAE, because at this concentration exogenous TNFα produced 
synaptic changes very similar, in both quality and quantity, to those observed in AT-EAE 
mice. While this value is much higher than the tissue concentration that we measured, it could 
mimic the TNFα concentration sensed by astrocytes locally, which may be orders of 
magnitude higher than the average concentration in the tissue (Wang et al., 2011). Regardless, 
600 pM exogenous TNFα and the endogenous cascade operating in AT-EAE appear to act via 
the same mechanism, as both enhance mEPSC frequency via astrocyte TNFR1 and an 
ifenprodil-sensitive mechanism. The latter data strongly suggests that TNFα activates at PP-
GC synapses the same pathway triggered by astrocyte GPRC agonists in physiological 
conditions, eventually resulting in stimulation of NR2B-containing pre-NMDAR (Jourdain et 
al., 2007; Santello et al., 2011), although the TNFα-induced activation must be different 
because it leads to long-lasting and irreversible modifications of synaptic activity. TNFα 
(upon prolonged incubation in normal mice) and the endogenous cascade of AT-EAE produce 
another common effect, a small increase in mEPSC amplitude. This effect is ifenprodil-
insensitive, and therefore mechanistically different from the astrocyte-mediated effect, which 
is clearly presynaptic. It could be, in contrast, post-synaptic, consistent with the reported 
capacity of TNFα to promote surface insertion of AMPAR subunits at dendritic spines via 
stimulation of neuronal TNFR1 (Stellwagen et al., 2005). The contribution of this latter 
mechanism to the synaptic and cognitive phenotype in AT-EAE remains to be defined given 
the substantial restoration of the phenotype upon TNFR1 re-expression selectively in 
astrocytes. 
  
Local malfunction of the entorhinal cortex-hippocampal excitatory circuit 
 15 
The TNFα/TNFR1-dependent synaptic changes identified here lead to alteration of the input-
output relationship in the EC-DG circuit, which is critically involved in contextual memory 
processing (Liu et al., 2012; Denny et al, 2014). Accordingly, we find altered contextual 
learning and memory performance in AT-EAE mice with increased TNFα levels in dorsal 
hippocampus. A persistently increased excitatory drive may reduce the dynamic range and 
impair long-term potentiation (LTP) (Goussakov et al., 2000; Pascual et al., 2005), a defect 
already observed in the DG with TNFα concentrations similar to those used in this study 
(Cunningham et al., 1996), and likely to cause abnormal processing of learning and memory-
related information (Chapman et al., 1999; Tombaugh et al., 2002). Definitive proof of the 
causative role played by the observed synaptic alterations could be achieved by reducing the 
abnormal excitatory PP input to GCs in AT-EAE mice in vivo, e.g. optogenetically, and 
showing consequent amelioration of the cognitive deficit. Such deficit appears in temporal 
overlap with a local inflammation pathology restricted to the hippocampal areas surrounding 
the 3rd ventricle, notably the DG (Fig 5B, large field). This suggests that the cognitive 
phenotype is locally-generated and not due to a generalized inflammatory state of the brain, 
although it does not exclude other sites of local inflammation in other brain regions at these 
stages of the pathology (Haji et al., 2012), nor that other behavioral processes, e.g. auditory 
fear, might be impacted (Acharjee et al., 2013). Putting all the above data together, we 
propose that a causal chain links EAE local inflammation to synaptic alteration and cognitive 
dysfunction via the action of TNFα and its astrocyte TNFR1. In this context, our data bring 
together a number of sparse recent observations suggesting that TNFα is involved in the 
synaptic alterations observed in EAE and other CNS pathology models (Centonze et al., 2009; 
Haji et al., 2012; Xu et al., 2010; Yang et al., 2013) and that enhanced TNFα levels are 
associated with the manifestation of cognitive defects (Belarbi et al., 2012; Gabbita et al., 
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2012; Terrando et al., 2010, reviewed in Clark et al. 2010; Swardfager and Black 2013; but 
see Han et al. 2013).  
 
Relevance for cognitive dysfunction in MS and other medical conditions 
While cognitive disturbances involving hippocampal alterations (Gold et al., 2010) affect a 
large number of MS patients (Chiaravalloti and DeLuca, 2008), the responsible mechanisms 
have remained elusive. The present findings provide a plausible mechanistic basis and also 
suggest that the mechanism responsible for cognitive dysfunction is distinct from the one 
causing the motor symptoms. In addition to MS, our findings may be relevant to other CNS 
pathologies characterized by cognitive disturbances and elevated grey matter TNFα levels, 
notably Alzheimer’s disease (McAlpine and Tansey, 2008; AD). Indeed, in animal models of 
AD, TNFα signaling via TNFR1 has been implicated in learning and memory deficits (He et 
al., 2007). Other inflammatory states due to bacterial or viral infections directly affecting the 
CNS, and even peripheral inflammatory states that result in septic encephalopathy are 
accompanied by cognitive disturbances (Clark et al., 2010; Swardfager and Black, 2013). 
They could therefore present synaptic alterations similar to those recognized in AT-EAE 
mice, caused by the identified astrocytic pathway. In view of these considerations, therapeutic 
agents targeting the described signaling steps, specifically astrocytic TNFR1 and pre-
NMDAR, could be tested against cognitive disturbances in the above medical conditions. 
TNFR1 has been strongly implicated in the pathogenesis of MS (Gregory et al., 2012) and 
EAE (Kassiotis and Kollias, 2001), but not yet in the cognitive aspects. According to animal 
studies and recent clinical trials selective blockade of TNFR1 function represents a promising 
therapeutic strategy in MS (Van Hauwermeiren et al., 2011). Development of TNFR1 
antagonists with central action could offer the important additional advantage of tackling the 
cognitive component of the pathology. As for pre-NMDAR, at hippocampal synapses these 
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receptors contain the NR2B subunit (Jourdain et al., 2007). NR2B antagonists are currently 
under clinical investigation in several neurologic and psychiatric disorders (Paoletti et al., 
2013). For effective use against cognitive impairment in MS and other conditions, more 
selective “presynaptic NR2B agents” or agents acting on other subunits typical of pre-
NMDAR (Larsen et al., 2011) should, however, be developed.  
 
 
EXPERIMENTAL PROCEDURES  
 
Animal models 
tnfr1−/− mice (Rothe et al., 1993), tnfr1cneo/cneo mice (Victoratos et al., 2006) and hGFAPcreT2 
mice (Hirrlinger et al., 2006) expressing a conditional EYFP reporter in the ROSA locus 
(Srinivas et al., 2001), all on C57BL/6 background, were generated and maintained as 
described in the original studies. The latter two lines were cross-bred to generate 
hGFAPcreT2/tnfr1cneo/cneo mice. To achieve gene recombination, hGFAPcreT2/tnfr1cneo/cneo 
and tnfr1cneo/cneo mice were administered TAM (100 mg/kg) dissolved in corn oil (OIL), or 
OIL alone as a control carrier, once per day for 8 consecutive days (Hirrlinger et al., 2006). 
For AT-EAE induction, mice were injected with effector MOG35-55-specific CD4+ T cells 
generated from 2D2 mice (details in Codarri et al. (2011)). Intervals from the first TAM or 
OIL injection were: 10-12 days in electrophysiology experiments without AT-EAE induction; 
16-22 days if AT-EAE was induced; 13-16 days in behaviour experiments in AT-EAE mice; 
13 days (young mice) and 25 days (adult mice) in immunohistochemistry experiments looking 
at EYFP reporter expression; 16-22 days in the same experiments looking at inflammation 
markers.  
 
Electrophysiology experiments  
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Patch-clamp recordings were performed in acute brain horizontal slices at excitatory PP-GC 
synapses in the hippocampal DG. GCs were patched with borosilicate glass pipettes (3-5 MΩ) 
and voltage-clamped at –65 mV. All experiments were carried out at 34ºC in the presence of 
picrotoxin (100 µM), to block GABAA receptor-mediated currents. To study mEPSC activity 
in isolation, tetrodotoxin (TTX, 1 µM) was added to block action potentials. To test the effect 
of TNFα (60-600 pM), the cytokine was locally applied via an ejection pipette positioned in 
the OML by using a single 10 s pulse (4-7 psi) delivered by a PV830 Pneumatic PicoPump 
(WPI, Germany). In some experiments we indirectly verified spatial diffusion and rapid 
washout of TNFα by co-ejecting Cascade blue, a fluorescent dye, under two-photon imaging. 
Recordings in each GC started about 10 min after reaching whole-cell and covered a period 
going from 5 min before to 30 min after TNFα application. Stimulation of the PP was done 
with a theta electrode placed in the OML. Recordings were analyzed essentially as described 
in Jourdain et al. (2007) and Santello et al. (2011). 
 
Immunohistochemistry 
For immunofluorescence staining, 50-µm-thick horizontal slices were prepared from fixed 
brains by use of a cryo-microtome (Microm International AG). After permeabilization, slices 
were incubated with primary antibodies (72 h, 4°C) and then with secondary antibodies in 
0.3% triton-X 100/PBS (2h, room temperature) and with 4′,6 -diamidino-2-phenylindole 
(DAPI, 300 nM) to label nuclei. Large field images in the hippocampus and neighboring 
regions were acquired using a Leica MZ16FA stereomicroscope (Leica Microsystems, 
Germany) equipped with Leica EL6000 illumination. In all other cases, images were acquired 
with a Leica SP5 AOBS confocal microscope (Leica Microsystems, Germany), using a 40x 
oil immersion “HCX PL APO” objective (NA: 1.25-0.75). Analysis was done with ImageJ 
software (NIH, USA).  
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Behavioural experiments 
Acquisition of contextual fear conditioning followed 24 h later by a test of its expression 
(sometimes repeated at 48h) were used as tests of, respectively, contextual learning and 
memory. The fear conditioning test, in some cases preceded by an open field test the day 
before, was carried out using a fear conditioning arena (context) with a grid floor which could 
be electrified, placed within an isolation chamber (Ugo Basile, Italy) controlled by Ethovision 
XT software (Noldus, Netherlands). Mice were first given a 5-min activity test (AT) without 
electroshocks to assess locomotor activity, baseline freezing and rearing. Next the 
conditioning session comprised six inescapable electroshocks (0.20 mA x 2 s each), delivered 
at 2 min intervals. After this test, mice were returned to their home cages until the following 
day, when they were placed back in the same arena in the absence of electroshocks for the 
mnemonic fear expression test. Mice were considered to be freezing if no movement was 
detected for at least 2 s and the measure was expressed as a percentage of time spent freezing.  
 
A detailed description of all experimental methods is provided in the Supplemental 
Experimental Procedures.  
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FIGURE LEGENDS 
 
Figure 1: Concentration-Dependent Effects of Exogenous TNFα on Excitatory Synaptic 
Activity in a Hippocampal Cognitive Circuit. A, left: two-photon image of the experimental 
setting for local TNFα application in the hippocampal DG (GC: green, Alexa-488; astrocytes: 
red, sulforhodamine 101; TNFα diffusion upon 10s local puff: Cascade blue with dotted white 
contour). Scale bar: 20 µm; GCL = granule cell layer; IML, MML and OML = inner, middle 
and outer molecular layer, respectively. A, right: representative traces of mEPSC activity in 
control condition (grey) and 30 min after puffing 60 pM TNFα (azure) or 600 pM TNFα 
(red); scale bars: 20 s, 20 pA. Insets: representative mEPSC events for each condition taken at 
the indicated time (triangle); scale bars: 10 ms, 5 pA. B, left: histograms of mean mEPSC 
frequency in control condition (n = 16) and 30 min after puffing 60 pM TNFα (n = 5) or 600 
pM TNFα (n =11). Only the latter treatment increases mEPSC frequency vs. control (p<0.001, 
ANOVA followed by post hoc comparisons: ANOVA + phc). B, middle: representative 
cumulative probability plots comparing mEPSC inter-event intervals (IEI) in the above 
conditions. B, right: mEPSC activity monitored from 5 min before puffing TNFα (puff 
denoted by arrow) to 30 min after puffing; azure: 60 pM TNFα; red: 600 pM TNFα. Only the 
latter increases mEPSC frequency (repeated measures ANOVA + phc: at 3, 5, 15 and 30 min: 
p<0.01; at 10, 20 and 25 min: p<0.001). C: histograms (left) and cumulative probability plots 
(right) of mean mEPSC amplitude before (control) and 30 min after application of 60 pM or 
600 pM TNFα. Neither TNFα concentration produced an effect (p>0.1, ANOVA). D: 
comparison of the effect of 600 pM TNFα in young (n = 11) and adult (n = 14) mice. In both 
groups TNFα maximally increased mEPSC frequency within 10 min (p<0.001; 2-way 
repeated measures ANOVA + phc) with comparable effect (p>0.08). E, left: biocytin staining 
of the recorded GC showing location of the stimulating electrode and of the puffing pipette 
containing 60 pM TNFα, accompanied by representative traces (average of 6 consecutive 
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sweeps) showing paired EPSCs before and 30 min after TNFα puff. Scale bars: 40 ms; 200 
pA. E, middle: histograms of mean EPSC amplitude and paired-pulse ratio (PPR) in control 
condition and 30 min after puffing 60 pM TNFα (n = 5; p > 0.27 and p > 0.12, respectively). 
E, right: time-course of the effect of 60 pM TNFα on mean EPSC amplitude (normalized 
value). F, left: GC biocytin staining and corresponding EPSC traces recorded before and after 
puffing 600 pM TNFα (conditions like in E, left). Scale bars: 40 ms; 200 pA. F, middle: 
histograms represent mean eEPSC amplitude and PPR in control condition and 30 min after 
puffing 600 pM TNFα. The cytokine causes substantial increase of EPSC amplitude (n = 9; p 
< 0.05) and decrease in PPR (n = 9; p < 0.01); F, right: time-course of the effect of 600 pM 
TNFα on mean EPSC amplitude (normalized value). TNFα induces progressive and 
irreversible increase in synaptic activity. Data are presented as mean ± SEM. See also Fig. S1. 
 
Figure 2: Mechanism of The Synaptic Change Induced By TNFα: Role of Ifenprodil-Sensitive 
NMDA Receptors and of TNFR1. A, B, C, left: representative traces of mEPSC frequency in a 
GC before (control) and 30 min after puffing 600 pM TNFα (different conditions in A, B and 
C specified below); right: time-course of the mean effect of TNFα (normalized value); Scale 
bars: 5 pA; 5 s. Statistics: repeated measures ANOVA + phc. A, TNFα effect in the presence 
of the NR2B-selective NMDAR antagonist ifenprodil (3 µM, blue bar). The cytokine does not 
change mEPSC frequency (n = 4, p>0.5 at all time-points after TNFα vs. before TNFα); B: 
TNFα effect when ifenprodil is applied 10 min after puffing the cytokine (ifenprodilpost). 
Ifenprodil does not reverse the mEPSC frequency increase induced by TNFα (n = 4; p<0.05: 
at 5 min post TNFα; p<0.01 at 10 and 20 min; p< 0.001: at 30 min vs. before TNFα); C: 
TNFα effect in tnfr1-/- mice. Lack of TNFR1 prevents the effect of TNFα (n = 4; p > 0.4 at all 
time-points after TNFα vs. before TNFα). Data are presented as mean ± SEM. 
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Figure 3: Characterization of hGFAPcreT2/tnfr1cneo/cneo Mice, a Model of Conditional 
TNFR1 Knock-out in Which TNFR1 Can Be Re-expressed Selectively in Astrocytes. A: 
scheme of the model: mice expressing TAM-inducible cre recombinase under the hGFAP 
promoter (hGFAPcreT2) and a conditional reporter (STOP-EYFP, grey triangles) in the 
ROSA locus are crossed with mice (tnfr1cneo/cneo) with a neomycin cassette (Neo-STOP) 
flanked by loxP sites inserted in the tnfr1 gene to conditionally inhibit its functional 
expression. B: representative immunolabeling of the hippocampal DG of a P90 
hGFAPcreT2/tnfr1cneo/cneo mouse upon TAM-induced recombination (z-stack = 12 µm; scale 
bar = 100 µm). Upper panels: left: reporter expression revealed by anti-EYFP antibodies 
(EYFP, red); middle: astrocyte staining with glutamine synthetase (GS, green); right: overlay 
showing co-localization of the reporter with astrocytes in the dentate ML and hilus. Notice 
few additional EYFP+ cells in the sub-granular zone (SGZ), representing neural stem cells 
and/or neuronal precursors. Blue: DAPI nuclear staining. Lower panels: left: reporter 
expression as above; middle: neuronal staining with NeuN (turquoise); right: overlay 
showing no co-localization of the reporter with neurons. (See also Fig. S2 for immunolabeling 
of OIL-treated hGFAPcreT2/tnfr1cneo/cneo mice). C: genomic PCR analysis of tnfr1 expression 
in FACS sorted neuronal (NeuN+) and non-neuronal (NeuN-) cell populations from the brains 
of TAM-injected hGFAPcreT2/tnfr1cneo/cneo, tnfr1cneo/cneo and wild-type mice. The lower band 
(407 bp) corresponds to the wild-type tnfr1 sequence; the upper one (Unrec, 1836 bp) to the 
presence of the neo cassette in the tnfr1 sequence (lack of tnfr1 expression); the intermediate 
band (Rec, 576 bp) to the removal of the neo cassette sequence between the 2 loxP sites upon 
recombination (tnfr1 re-expression). Note the combined appearance of a strong Rec band and 
a reduced Unrec band selectively in the NeuN- population from TAM-injected 
hGFAPcreT2/tnfr1cneo/cneo mice. See also Fig S3 and 4. The β-actin promoter amplicon 
(bottom) shows the presence of similar amounts of DNA in the reactions. On the left: 
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molecular weight marker: 100 bp DNA ladder. The gel was cut below 100bp for aesthetic 
reasons. 
 
Figure 4: Re-Expression of TNFR1 Selectively in Astrocytes Reconstitutes the Synaptic Effect 
of TNFα. A, B. C left: representative traces of mEPSC frequency in a GC before (control) and 
30 min after puffing 600 pM TNFα (different conditions in A, B and C specified below); 
right: time-course of the mean effect of TNFα (normalized value); Scale bars: 5 pA, 5 s; 
Statistics: repeated measures ANOVA + phc. A: TNFα effect in TAM-injected 
hGFAPcreT2/tnfr1cneo/cneo mice. The cytokine induces persistent increase in mEPSC 
frequency (n = 7; p<0.01 at all time-points after TNFα vs. before TNFα); B: TNFα effect in 
OIL-injected hGFAPcreT2/tnfr1cneo/cneo mice. Without TAM-induced recombination, TNFα 
does not change mEPSC frequency (n = 3; p >0.3 at all time-points after TNFα vs. before 
TNFα); C: TNFα effect in TAM-injected tnfr1cneo/cneo mice. With TAM but without cre 
activity, TNFα does not change mEPSC frequency (n = 5; p > 0.2 at all time-points after 
TNFα vs. before TNFα.  Data are presented as mean ± SEM. 
 
Figure 5: Impaired Cognitive Function, Local Inflammation and Enhanced TNFα Levels in 
the Hippocampus of AT-EAE Mice. A: contextual fear learning and memory test in AT-EAE 
mice (6-7 dpi; blue, n = 7, see also Figs. S5 and S6) vs. vehicle-injected control mice (grey, n 
= 7); left: acquisition of contextual fear conditioning. Mice were first exposed to an activity 
test (AT) and then to contextual fear conditioning (see also Fig. S6). The two groups 
displayed similar increase in % time spent freezing across intervals (Interval main effect 
p<0.001 ANOVA + phc) with AT-EAE mice showing slightly lower values; right: 
expression of fear conditioning. AT-EAE mice exhibited decreased freezing (reduced fear 
memory) compared to control mice (Group x Interval interaction p<0.001 ANOVA + phc) at 
intervals 1-3, 4-6 and 7-9 (p<0.01; 0.05 and 0.001 respectively). In control mice the level of 
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freezing at the onset of the expression test was equivalent to that at the end of acquisition. B: 
representative labeling of microglia and leukocyte markers (Iba1, red; CD11b, green) in the 
hippocampus at the border with the 3rd ventricle (3rd V) in control condition and after AT-
EAE induction; blue: DAPI nuclear staining; left: large field view (scale bar = 500 µm). 
Notice in AT-EAE mice (14 dpi) strong accumulation of CD11b-and/or Iba1-positive cells in 
the 3rd V and surrounding regions (DG and CA3), dissipating towards more distal regions 
(CA1 and CA2). Middle: enlarged views of the DG (ML, GCL) at the border with the 3rd V, 
corresponding to the dotted squares on the left. The three panels compare the situation in 
control mice and in AT-EAE mice at 8 and 14 dpi (z-stack = 45 µm; scale bar = 50 µm). An 
increasing number of infiltrating leukocytes (CD11b+) and activated microglia (Iba1+ and 
CD11b+) are seen with progression of AT-EAE pathology. Right: enlarged views (scale bar = 
5 µm) of the white frames in the middle panels highlight the state change of microglia, from 
resting in control mice (faint Iba1staining) to activated in AT-EAE mice (14 dpi; strong 
Iba1staining); C: TNFα levels in the hippocampus of control (n = 7) and AT-EAE mice (8 
dpi; n = 7; same mice as in A). Histograms show significant increase in AT-EAE mice 
compared to controls, specifically in dorsal vs. ventral hippocampus (p<0.05; ANOVA + 
phc). In controls, TNFα values in dorsal and ventral hippocampus were analogous and 
grouped together. Data are presented as mean ± SEM. 
 
Figure 6: Altered Hippocampal Excitatory Transmission in AT-EAE: Protective Effect of 
Ifenprodil. A, top: representative traces of evoked paired-pulse EPSCs in GCs from wild-type 
vehicle-treated (control, grey) and AT-EAE mice (9 dpi, blue); Scale bars: 40 ms; 200 pA. 
Stimulation was adjusted to obtain comparable initial EPSC amplitudes in the two groups. 
Short-term plasticity is altered in AT-EAE mice, leading to reduced paired-pulse facilitation. 
Histograms show mean PPR in the two conditions (control: n = 10; AT-EAE: n = 8; p < 
0.001, unpaired t-test); A, bottom: mean amplitudes of single EPSCs plotted as function of 
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the stimulus intensity. EPSCs are larger in GCs from AT-EAE mice than in GCs from control 
mice (n = 6 and 9, respectively; p<0.05, 2-way ANOVA + phc). B, top: representative traces 
of mEPSC activity in dentate GCs from control (n =16) and AT-EAE mice (12 dpi, n = 24). 
Scale bars: 20 s; 20 pA. The enlarged regions highlight an increased activity in AT-EAE 
mice. Scale bars: 2 s; 10 pA. B, bottom: histograms and representative cumulative probability 
plots of mean mEPSC frequency (left) and amplitude (right) in control mice and in AT-EAE 
mice. Both parameters are significantly enhanced in AT-EAE mice (p<0.001 and p<0.05, 
respectively, unpaired t-test). C, top: representative trace of mEPSC activity in dentate GCs 
from AT-EAE mice treated with ifenprodil in vivo (azure, n = 14). Scale bars: 20 s; 20 pA; the 
enlarged region shows that activity is lower compared to untreated AT-EAE mice and similar 
to controls. Scale bars: 2 s; 10 pA. C, bottom: histograms showing % change in mean 
mEPSC frequency (left) and amplitude (right) vs. control in AT-EAE mice treated (azure) or 
not (blue) with ifenprodil in vivo. Untreated but not ifenprodil-treated AT-EAE mice display 
higher mEPSC frequency than controls (p<0.001 and p = 0.28, respectively, ANOVA + phc). 
Concerning mEPSC amplitude, both ifenprodil-treated and untreated AT-EAE mice display 
higher amplitude than controls (p<0.05, ANOVA + phc).  Data are presented as mean ± SEM. 
 
Figure 7: Causal Role of Astrocyte TNFR1 Signaling in the Hippocampal Synaptic 
Alterations and Cognitive Impairment Induced by AT-EAE. A, left: representative traces of 
mEPSC activity in dentate GCs upon induction of AT-EAE in mice re-expressing TNFR1 
selectively in astrocytes (TAM-treated hGFAPcreT2/tnfr1cneo/cneo, dark red; n = 21) and in 
their direct controls (OIL-treated hGFAPcreT2/tnfr1cneo/cneo, grey; n = 11). Scale bars: 20 s; 20 
pA. The enlarged regions highlight higher mEPSC activity in TAM-treated mice compared to 
OIL-treated ones. Scale bars: 2 s; 10 pA. A, middle: histograms showing that mean mEPSC 
frequency is significantly higher in TAM-treated vs. OIL-treated hGFAPcreT2/tnfr1cneo/cneo 
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AT-EAE mice (p<0.05, unpaired t-test). A, right: representative cumulative probability plots 
comparing mEPSC IEI in the two above groups. B: Histograms showing comparative changes 
in mEPSC frequency in GCs induced by AT-EAE in several groups of mice with respect to 
wild-type controls. AT-EAE groups are: wild-type mice (blue, n = 16), TAM- (dark red, n = 
21) and OIL-treated (grey, n = 11) hGFAPcreT2/tnfr1cneo/cneo mice; TAM- (gold, n = 15) and 
OIL-treated (green, n = 19) tnfr1cneo/cneo mice. AT-EAE causes mEPSC frequency increase 
only in wild-type and TAM-treated hGFAPcreT2/tnfr1cneo/cneo mice (p < 0.001 and p <0.05 vs 
wild-type controls, respectively; ANOVA + phc). The latter two groups are not statistically 
different (p = 0.095, ANOVA). C: representative labeling of microglia and leukocyte markers 
(Iba1, red; CD11b, green) in the hippocampal DG of TAM- or OIL-treated 
hGFAPcreT2/tnfr1cneo/cneo (top) and tnfr1cneo/cneo (bottom) AT-EAE mice. The pattern of local 
leukocyte infiltration and microglia activation is similar in the 4 groups of mice and resembles 
the one observed in wild-type AT-EAE mice (see Fig. 5B); z-stack = 20 µm; scale bar: 50 
µm. D: contextual fear learning and memory test in TAM-treated hGFAPcreT2/tnfr1cneo/cneo 
(dark red, n = 21), OIL-treated hGFAPcreT2/tnfr1cneo/cneo (grey, n = 12) and TAM-treated 
tnfr1cneo/cneo mice (gold, n = 11) developing AT-EAE (6-8 dpi). D, left: mice were first 
exposed to an activity test (AT) and then to contextual fear conditioning (see also open field 
data, Fig. S7). For acquisition of fear conditioning, all groups displayed increased % time 
spent freezing (Interval main effect p<0. 001, ANOVA + phc). However, TAM-treated 
hGFAPcreT2/tnfr1cneo/cneo mice acquired less fear conditioning than did their OIL-injected 
counterparts and TAM-treated tnfr1cneo/cneo mice (Group x Interval interaction p<0.003 
ANOVA + phc), whereas the latter two groups were not different; D, middle: fear expression 
test 24h later: there was no difference among the three groups although TAM-treated 
hGFAPcreT2/tnfr1cneo/cneo mice showed a trend to reduced freezing (Group main effect p=0.06 
ANOVA). D, right: repetition of the fear expression test the next day (48h after 
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conditioning). TAM-treated hGFAPcreT2/tnfr1cneo/cneo mice showed a further decrease in 
freezing and exhibited decreased freezing compared to the other two groups (Group main 
effect p<0.002 ANOVA + phc), whereas OIL-treated hGFAPcreT2/tnfr1cneo/cneo mice and 
TAM-treated tnfr1cneo/cneo mice exhibited similar % time freezing. Asterisks are color-coded 
and refer to comparison with TAM-treated hGFAPcreT2/tnfr1cneo/cneo mice. Data are presented 
as mean ± SEM. 
   
   
  
  
  
  
  
  
   
  
 
  
  
  
  
  
  
  
 
